Lord's Mark Industries Ltd has acquired Renalyx Health Systems Private Limited for an undisclosed amount. Renalyx, established in 2012 in Bengaluru, India, is a technology innovation company dedicated to providing comprehensive renal care solutions. It focuses on developing advanced technologies for the screening, management, and treatment of Chronic Kidney Disease (CKD).
Renalyx is an ISO 13485 Certified Medical Devices company, notably designing and developing India's first HemoDialysis Machine. Its product portfolio includes solutions for early CKD detection, utilizing patented microalbumin and creatinine strips alongside a mobile application for managing disease stages 1-4. The company also offers PHC Dialysis Machines (RxT17) and Sustained Low Efficiency Dialysis (SLED) Machines (RxT21) for intensive care units, both featuring remote monitoring capabilities. Additionally, Renalyx has developed a cloud-based Digital Nephrology Platform to automate dialysis workflows, reporting, and remote machine supervision.
This acquisition is strategically significant for Lord's Mark Industries Ltd, enhancing its footprint within the medical devices and healthcare technology sector. By integrating Renalyx, Lord's Mark gains proprietary technology and a robust product line addressing a critical area of public health. Renalyx's commitment to inclusive, affordable, and accessible dialysis treatment aligns with broader healthcare market needs, particularly in India.
The combined entity is expected to realize synergies through expanded market reach and strengthened research and development capabilities. Lord's Mark can leverage its scale and resources to further Renalyx's innovations, potentially accelerating the deployment of advanced renal care solutions. This integration aims to create a more comprehensive offering in renal diagnostics and treatment, streamlining processes and improving patient access.
Moving forward, the acquisition positions Lord's Mark Industries Ltd to become a more dominant player in the renal care segment, offering an integrated suite of products from early detection to advanced dialysis treatment, thereby addressing the growing burden of kidney disease.